213 related articles for article (PubMed ID: 38417915)
1. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies.
Rao A; Agrawal A; Borthakur G; Battula VL; Maiti A
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417915
[TBL] [Abstract][Full Text] [Related]
2. Identification of the immunosuppressive effect of γδ T cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia.
Liang S; Dong T; Yue K; Gao H; Wu N; Liu R; Chang Y; Hao L; Hu L; Zhao T; Jiang Q; Huang XJ; Liu J
Front Immunol; 2022; 13():1009709. PubMed ID: 36325350
[TBL] [Abstract][Full Text] [Related]
3. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia.
Klyuchnikov E; Badbaran A; Massoud R; Fritsche-Friedland U; Janson D; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2021 Oct; 27(10):841-850. PubMed ID: 34118468
[TBL] [Abstract][Full Text] [Related]
6. Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.
Pistoia V; Tumino N; Vacca P; Veneziani I; Moretta A; Locatelli F; Moretta L
Front Immunol; 2018; 9():984. PubMed ID: 29867961
[TBL] [Abstract][Full Text] [Related]
7. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.
Perko R; Kang G; Sunkara A; Leung W; Thomas PG; Dallas MH
Biol Blood Marrow Transplant; 2015 Jan; 21(1):130-6. PubMed ID: 25445640
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells.
Gundermann S; Klinker E; Kimmel B; Flierl U; Wilhelm M; Einsele H; Kunzmann V
J Immunother; 2014; 37(6):321-30. PubMed ID: 24911793
[TBL] [Abstract][Full Text] [Related]
9. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
[TBL] [Abstract][Full Text] [Related]
10. The role of gamma delta T cells in haematopoietic stem cell transplantation.
Minculescu L; Sengeløv H
Scand J Immunol; 2015 Jun; 81(6):459-68. PubMed ID: 25753378
[TBL] [Abstract][Full Text] [Related]
11. Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia.
Jin Z; Luo Q; Lu S; Wang X; He Z; Lai J; Chen S; Yang L; Wu X; Li Y
J Hematol Oncol; 2016 Nov; 9(1):126. PubMed ID: 27863523
[TBL] [Abstract][Full Text] [Related]
12. STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2
Cheng C; Liang S; Yue K; Wu N; Li Z; Dong T; Dong X; Ling M; Jiang Q; Liu J; Huang XJ
Cancer Lett; 2024 Apr; 587():216730. PubMed ID: 38360140
[TBL] [Abstract][Full Text] [Related]
13. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic avenues for γδ T cells in cancer.
Costa GP; Mensurado S; Silva-Santos B
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007241
[TBL] [Abstract][Full Text] [Related]
15. High
Kong X; Zheng J; Liu X; Wang W; Jiang X; Chen J; Lai J; Jin Z; Wu X
Front Immunol; 2022; 13():823352. PubMed ID: 35222403
[TBL] [Abstract][Full Text] [Related]
16. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
17. Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.
Branella GM; Lee JY; Okalova J; Parwani KK; Alexander JS; Arthuzo RF; Fedanov A; Yu B; McCarty D; Brown HC; Chandrakasan S; Petrich BG; Doering CB; Spencer HT
Front Immunol; 2023; 14():1294555. PubMed ID: 38022523
[TBL] [Abstract][Full Text] [Related]
18. γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation.
Wu N; Liu R; Liang S; Gao H; Xu LP; Zhang XH; Liu J; Huang XJ
Front Immunol; 2021; 12():687961. PubMed ID: 34335589
[TBL] [Abstract][Full Text] [Related]
19. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
20. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Knight A; Piskacek M; Jurajda M; Prochazkova J; Racil Z; Zackova D; Mayer J
Cancer Immunol Immunother; 2023 May; 72(5):1209-1224. PubMed ID: 36376516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
